STOCK TITAN
  1. Home
  2. Sec-filings
  3. SBEV
  4. [8-K] SPLASH BEVERAGE GROUP, INC. Reports Material Event

Splash Beverage (NYSE: SBEV) pivots to cannabinoid health, rebrands as Endovia

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Splash Beverage Group, Inc. (SBEV) announced that its corporate name will change to Endovia Health Sciences, Inc. and its common stock will begin trading on the NYSE American under the new ticker “EDVA” effective at 9:30 a.m. Eastern Time on Monday, August 24, 2026. This name and ticker change reflects an ongoing strategic transformation from legacy beverage operations into a diversified cannabinoid-based health sciences platform focused on pharmaceutical, FDA-regulated human and veterinary therapeutics, and cannabinoid-based consumer wellness and beverage products.

The company highlighted progress in its CannEpil® program, including opening an Investigational New Animal Drug file with the FDA’s Center for Veterinary Medicine, and stated that existing stockholder rights and stock certificates remain unchanged, with no action required by shareholders. The press release also outlines significant risks, including the need to raise capital, maintain key licenses, meet debt obligations, obtain regulatory approvals and comply with NYSE American continued listing standards.

Positive

  • Strategic shift into cannabinoid-based health sciences, expanding focus to pharmaceutical, FDA-regulated human and veterinary therapeutics, and cannabinoid-based consumer wellness and beverage products.
  • Regulatory advancement for CannEpil® through opening an Investigational New Animal Drug (INAD) file with the FDA’s Center for Veterinary Medicine for its veterinary development program in the United States.

Negative

  • Significant capital needs disclosed, including the risk of not raising sufficient funds to finance operations and the business and product development plan.
  • Dependence on CannEpil® license and regulatory success, including the risk of failing to maintain the license, complete studies, or obtain and maintain required authorizations.
  • Debt and listing risks, including the ability to meet debt obligations and explicit risk of failing to comply with NYSE American continued listing standards, which could lead to delisting.

Filing Explained

The filing identifies raising capital to fund operations and development as a risk; at June 30, 2026, the company’s $242,702 cash and equivalents equaled 20 days of the last reported operating cash use, providing liquidity context rather than a new financing commitment.

Sources and calculations
  • Cash and equivalents vs quarterly operating cash outflow, in days of cash use $242,702 / ($1,091,680 / 90) = [object Object]
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Trading effective date and time under ticker EDVA 9:30 a.m. Eastern Time on Monday, August 24, 2026 Effective time when common stock begins trading on NYSE American as EDVA
Form 10-K reporting period Year ended December 31, 2025 Period covered by the referenced Annual Report on Form 10-K
Form S-1/A filing date August 20, 2026 Date of the referenced Form S-1/A filing with the SEC
Investigational New Animal Drug (INAD) regulatory
"advanced its CannEpil® veterinary development program by opening an Investigational New Animal Drug (INAD)"
Investigational New Animal Drug (INAD) is a regulatory designation and file that allows a company to study a new veterinary drug in animals under government oversight before it can be approved for sale. It documents permitted testing plans, safety and efficacy data collection, and manufacturing controls. For investors, an INAD indicates a drug is in the formal development and review phase, affecting timelines, development costs, regulatory risk, and the potential size and timing of future market opportunity, analogous to a permit to prototype before commercial launch.
Center for Veterinary Medicine regulatory
"with the U.S. Food and Drug Administration’s Center for Veterinary Medicine, establishing the regulatory framework"
A Center for Veterinary Medicine is the regulatory office that evaluates and oversees the safety and effectiveness of medicines, medical devices, and food additives for animals. Think of it as a gatekeeper that decides which animal health products can be sold and under what rules; those decisions shape market access, product labeling, approval timelines, and the risk of recalls, all of which directly affect a company’s sales prospects and investor value.
cannabinoid-based health sciences platform medical
"transformation from its legacy beverage operations into a diversified cannabinoid-based health sciences platform"
forward-looking statements regulatory
"This press release contains forward-looking statements within the meaning of applicable securities laws"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
continued listing standards regulatory
"our ability to comply with NYSE American’s continued listing standards and the risk that we may be delisted"
Ongoing rules a stock exchange requires a listed company to meet to keep its shares trading publicly, such as minimum share price, market value, timely financial reports, and governance practices. Think of it as a membership checklist for a club: falling short can lead to warnings or removal from the exchange, which can sharply reduce liquidity, investor confidence, and a stock’s value. Investors watch these standards to gauge regulatory risk and the stability of their holdings.

FAQ

What corporate name change did SBEV announce?
Splash Beverage Group, Inc. announced that its corporate name will change to Endovia Health Sciences, Inc. as part of its strategic transformation into a diversified cannabinoid-based health sciences platform.

When will SBEV start trading under the new ticker EDVA?
The company’s common stock will begin trading on the NYSE American under the new ticker “EDVA” effective at 9:30 a.m. Eastern Time on Monday, August 24, 2026.

How does the name and ticker change affect SBEV shareholders?
The company states that the name and ticker change will not affect shareholder rights. Existing stock certificates will remain valid, and no action is required by shareholders in connection with the change.

What new strategic focus is SBEV (Endovia) pursuing?
Endovia Health Sciences is focusing on a diversified cannabinoid-based health sciences platform, centered on commercial pharmaceutical assets, FDA-regulated human and veterinary therapeutics, and cannabinoid-based consumer wellness and beverage products.

What regulatory step has SBEV taken for its CannEpil veterinary program?
The company has opened an Investigational New Animal Drug (INAD) file with the FDA’s Center for Veterinary Medicine for its CannEpil® veterinary development program, establishing the regulatory framework for continued U.S. development.

Which recent SEC filings does SBEV reference for additional risk information?
The company refers investors to its Annual Report on Form 10-K for the year ended December 31, 2025 and its Form S-1/A filed on August 20, 2026 for additional risk information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
false 0001553788 0001553788 2026-08-21 2026-08-21 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 21, 2026

 

SPLASH BEVERAGE GROUP, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   001-40471   34-1720075

(State or other Jurisdiction

of Incorporation)

   (Commission File Number)  

(IRS Employer

Identification No.)

 

1112 N. Flagler Drive

Fort Lauderdale, Florida

   33304
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (954) 648-7238

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.001 par value   SBEV   NYSE American LLC

 

 

 

Item 7.01 Regulation FD Disclosure

 

On August 21, 2026, Splash Beverage Group, Inc. (the “Company”) issued a press release announcing that its corporate name will change to Endovia Health Sciences, Inc., and its common stock will begin trading on the NYSE American under the new ticker symbol “EDVA” effective at market open at 9:30 a.m. Eastern Time on Monday, August 24, 2026.

 

The name and ticker change mark an important milestone in the Company’s ongoing strategic transformation from its legacy beverage operations into a diversified cannabinoid-based health sciences platform.

 

A copy of the press release is furnished as Exhibit 99.1 of this Current Report on Form 8-K.

 

The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities under such section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits

 

Exhibit   Description
99.1   Press Release dated August 21, 2026
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  

  SPLASH BEVERAGE GROUP, INC.
     
Date: August 21, 2026 By: /s/ Brady Cobb
  Name: Brady Cobb
  Title: Interim Chief Executive Officer

 

 

 

 

EXHIBIT 99.1

 

Splash Beverage Group to Become Endovia Health Sciences; New NYSE American Ticker “EDVA” Effective Monday

 

New corporate identity and ticker reflect the Company’s transformation into a diversified cannabinoid-based health sciences platform

 

FORT LAUDERDALE, Fla., August 21, 2026 — Splash Beverage Group, Inc. (NYSE American: SBEV) (the “Company”) today announced that its corporate name will change to Endovia Health Sciences, Inc., and its common stock will begin trading on the NYSE American under the new ticker Times New Roman, Times, Serif “EDVA” effective at market open at 9:30 a.m. Eastern Time on Monday, August 24, 2026.

 

The name and ticker change mark an important milestone in the Company’s ongoing strategic transformation from its legacy beverage operations into a diversified cannabinoid-based health sciences platform.

 

The Company’s new corporate identity reflects its focus on three complementary areas: commercial pharmaceutical assets, FDA-regulated human and veterinary therapeutics, and cannabinoid-based consumer wellness and beverage products.

 

“This is more than a change in our name and ticker—it reflects the transformation of our business and the strategy we are executing,” said Brady Cobb, Interim Chief Executive Officer. “Over the past year, we began repositioning the Company around cannabinoid-based health sciences, acquiring differentiated pharmaceutical rights, expanding international commercialization opportunities and advancing CannEpil® through regulated human and veterinary development pathways.”

 

“Beginning Monday, investors will know us as Endovia Health Sciences, trading under the Times New Roman, Times, Serif EDVA. We believe the new identity better represents the business we are building and provides a platform from which we can execute our long-term strategy.”

 

Building Endovia Health Sciences

 

Endovia is building a diversified cannabinoid-based health sciences platform designed to translate science into regulated therapies and trusted health and wellness products for people and animals.

 

The Company’s strategy is centered on three complementary growth engines:

 

●Commercial Pharmaceutical Assets — Commercializing differentiated cannabinoid-based pharmaceutical products through international distribution and strategic partnerships.

 

●FDA-Regulated Therapeutics — Advancing cannabinoid-based human and veterinary therapeutics through established U.S. regulatory pathways.

 

●Consumer Wellness & Beverages — Developing cannabinoid-based wellness and beverage products as regulatory frameworks and commercial opportunities evolve.

 

The Company recently advanced its CannEpil® veterinary development program by opening an Investigational New Animal Drug (INAD) file with the U.S. Food and Drug Administration’s Center for Veterinary Medicine, establishing the regulatory framework for the program’s continued development in the United States.

 

“Our focus now is execution,” Cobb continued. “We have established the platform, expanded our pharmaceutical and veterinary opportunities, and created a corporate identity that aligns with our direction. The next phase is about achieving measurable regulatory and commercial milestones and building long-term value for our shareholders.”

 

 

 

New Corporate Identity

 

Effective Monday, August 24, 2026:

 

Corporate Name: Endovia Health Sciences, Inc.
NYSE American Ticker: EDVA
Trading Effective: 9:30 a.m. Eastern Time
Corporate Website: EndoviaSciences.com

 

The name and ticker change will not affect the rights of the Company’s shareholders. Existing stock certificates will remain valid, and no action is required by shareholders in connection with the change.

 

Our Vision

 

To build a diversified cannabinoid-based health sciences platform that translates science into regulated therapies and trusted health and wellness products for people and animals.

 

Our Mission

 

Endovia Health Sciences acquires, develops and commercializes differentiated cannabinoid-based health technologies across pharmaceutical, veterinary and consumer wellness markets. Through disciplined capital allocation, scientific excellence and strategic partnerships, we strive to build scalable businesses designed to deliver meaningful healthcare innovation and long-term shareholder value.

 

About Endovia Health Sciences, Inc.

 

Endovia Health Sciences, Inc. is prioritizing its efforts toward building a diversified cannabinoid-based health sciences platform focused on acquiring, developing and commercializing differentiated cannabinoid-based health technologies across pharmaceutical, veterinary and consumer wellness markets. The Company’s strategy combines international pharmaceutical commercialization, FDA-regulated human and veterinary development, and cannabinoid-based consumer wellness and beverage opportunities.

 

Where Science Meets Cannabinoid Innovation.

 

Cautionary Note Regarding Forward-Looking Statements

 

This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the Company’s strategic focus and transformation, name change, efforts toward the development and commercialization of CannEpil®, and FDA-regulated pharmaceutical products for humans and animals, international expansion and future business opportunities, consumer wellness and beverage opportunities, FDA regulatory activities, anticipated trends and expectations for the Company’s business and industry and goals and expectations with respect to the Company’s new business strategy as well as the Company’s ability to achieve regulatory, commercial and financial milestones.

 

Forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially. These risks include the Company’s ability to raise the necessary capital to finance the its operations and business and product development plan, satisfy its contractual obligations including our ability to maintain the license under the license agreement for the CannEpil® product on which the Company’s initial focus depends and related agreements in connection therewith, our ability to complete required studies, establish product safety and efficacy, obtain and maintain regulatory authorizations, protect intellectual property and the risk that competitors market the same or similar products, our ability execute commercialization or strategic-partnering arrangements, the risk that that the market or demand for any resulting product we seek to commercialize in the future could be less than expected or projected, our ability to meet our debt obligations and the negative financial and operational consequences of failing to do so, our ability to comply with NYSE American’s continued listing standards and the risk that we may be delisted, the possibility that our expectations and perceived benefits with respect to our business and product development plan and strategic transactions we may pursue prove to be incorrect, and risks with respect to our ability to negotiate and execute definitive agreements, satisfy closing conditions, obtain required approvals with respect to any such strategic transaction. There can be no assurance that the Company’s goals and milestones will be achieved, that the Company or its collaborators will receive or maintain necessary regulatory authorizations or that any initiative will ultimately generate revenue.

 

Additional risks are described in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025 and the Form S-1/A filed on August 20, 2026. The Company undertakes no obligation to update forward-looking statements except as required by applicable law.

 

 

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

4 documents

Press Releases

Other Documents